Composition comprising beta-mannanase
View Patent ↗Enzymes of a particular class, characterized by the ability to cleave a linkage that effects release of a cell-surface protein or carbohydrate, which does not contain an anti-infection agent, display significant anti-infectious activity. Upon oral administration, these enzymes are effective, for example, in the treatment of digestive tract infections in humans and in animals. In the latter, there are benefits of significantly improved growth rate, feed efficiency, and overall health.
1. A composition comprising (i) an endo-1,4-β-D-marmanase in an amount that is effective to treat or ameliorate the risk of digestive tract infection and (ii) a physiologically acceptable carrier for said mannanase, wherein said composition is adapted for oral administration and does not contain an anti-infection agent other than said mannanase.
2. The composition according to claim 1 , wherein said carrier is a foodstuff into which said endo-1,4-β-D-mannanase is incorporated.
3. The composition according to claim 2 , wherein said foodstuff is an animal feed.
4. The composition according to claim 3 , wherein said animal feed comprises grain material, a source of protein, vitamins, amino acids, and minerals.
5. The composition according to claim 4 , wherein said grain material is corn, sorghum, wheat, barley or oats.
6. The composition according to claim 4 , wherein said source of protein is beans or peas.
7. The composition according to claim 1 , wherein said composition is in a solid or a liquid formulation.
8. The composition according to claim 1 , wherein said endo-1,4-β-D-mannanase is contained in a tablet or gelatin capsule shell.
9. The composition according to claim 1 , wherein said endo-1,4-β-D-marmanase is prepared from a Bacillus lentus strain.
10. The composition according to claim 1 , wherein said endo-1,4-β-D-mannanase is obtained by expression of a recombinant DNA in a host organism.
11. The composition according to claim 10 , wherein said host organism is from a Bacillus megaterium strain.
12. The composition according to claim 1 , wherein said mannanase is the endo-1,4-β-D-mannanase produced by Bacillus lentus designated as ATCC 55045.
13. The composition according to claim 1 , wherein said mannanase cleaves a linkage that effects release of a cell-surface protein or carbohydrate.
14. The composition according to claim 1 , wherein said composition further comprises a stabilizer, a carbohydrate carrier or a preservative.
15. The composition according to claim 14 , wherein said stabilizer is a buffer, a carbohydrate or a glycol.
16. The composition according to claim 14 , wherein said carbohydrate carrier is selected from the group consisting of xylose, fructose, glucose, sorbitol, and maltotriose.
17. The composition according to claim 14 , wherein said preservative is selected from the group consisting of propylparaben, sodium sorbate, potassium sorbate, and ascorbyl palmitate.
18. The composition according to claim 3 , wherein said composition comprises 100 million units mannanase activity per ton of feed.
19. The composition according to claim 3 , wherein said composition comprises 121 million units mannanase activity per ton of feed.
20. The composition according to claim 3 , wherein said composition comprises 506 million units mannanase activity per ton of feed.
21. A method of treating or ameliorating the risk of a digestive tract infection, comprising orally administering to a subject, suffering from or at risk of said infection, an effective amount of a composition according to claim 1 , wherein said method does not include administering with said composition an antimicrobially effective amount of another anti-infection agent.
22. The method according to claim 21 , wherein said infection is caused by a protozoan, bacterial, yeast, or fungal pathogen.
23. The method according to claim 22 , wherein said infection is caused by a protozoan pathogen of the genus Eimeria.
24. The method according to claim 22 , wherein said infection is caused by a protozoan pathogen of the genus Cryptosporidium.
25. The method according to claim 22 , wherein said infection is caused by a bacterial pathogen of the genus Clostridium.
26. The method according to claim 21 , wherein said endo-1,4-β-D-mannanase is prepared from a Bacillus lentus strain.
27. The method according to claim 21 , wherein said endo-1,4-β-D-mannanase is obtained by expression of a recombinant DNA in a host organism.
28. The method according to claim 27 , wherein said host organism is from a Bacillus megaterium strain.
29. The method according to claim 21 , wherein said mannanase is the endo-1,4-β-D-mannanase produced by Bacillus lentus designated as ATCC 55045.
30. The method according to claim 21 , wherein said endo-1,4-β-D-mannanase cleaves a linkage that effects release of a cell-surface protein or carbohydrate.
31. The method of claim 21 , wherein the subject is poultry.
32. The method of claim 21 , wherein the subject is swine.